November 17, 2025

Sumedha Sinha Ph.D., RAC-Devices
Clinical Development Lead
Clinical Development and Medical Affairs
Roche Molecular Systems, Inc.
4300 Hacienda Drive
Pleasanton, CA 94588

Re: Revocation of EUA230038

Dear Dr. Sinha:

This letter is in response to the request from Roche Molecular Systems, Inc., in a letter dated August 29, 2025, that the U.S. Food and Drug Administration (FDA) revoke the EUA for the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, which includes the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit, issued on June 7, 2024, and revised on August 9, 2024.

Roche Molecular Systems, Inc. indicated that they have ceased the manufacture and distribution of the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test reagents for the EUA labeled product, which includes the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit, and requested that the EUA be revoked. As of the date of this letter Roche Molecular Systems, Inc., has fully transitioned to the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test that was cleared under K243406/CW240026.

FDA understands that as of the date of this letter Roche Molecular Systems, Inc. has ceased the manufacture and distribution of the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test reagents, which also includes the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit, for the EUA labeled product, but that there remains some viable EUA labeled product in distribution in the United States.

The authorization of a device for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb-3) may, pursuant to section 564(g)(2) of the Act, be revoked when circumstances make such revocation appropriate to protect the public health or safety (section 564(g)(2)(C) of the Act). Because Roche Molecular Systems, Inc. has requested that FDA revoke the EUA for the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, which includes the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit, FDA has determined that it is appropriate to protect the public health or safety to revoke this authorization. Accordingly, FDA hereby revokes EUA230038 for the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, pursuant to section 564(g)(2)(C) of the Act. As of the date of this letter, the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, which includes the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit, is no longer authorized for emergency use by FDA.

As discussed, FDA does not intend to object to the use of any remaining viable inventory of the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, which includes the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit and that is the EUA labeled product that was distributed prior to revocation of the EUA per Roche Molecular Systems, Inc.'s plan to recommend that such product be used in conjunction with the cleared package insert/manufacturer instructions for use cleared as part of the April 25, 2025, 510(k) cleared cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test. Importantly, the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test product for which FDA had issued an EUA and the product that FDA has cleared under 510(k) are manufactured under the same quality system with the same lot release criteria. We request that Roche Molecular Systems, Inc. instruct customers who have remaining cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test EUA-labeled product inventory to use their EUA product in combination with the package insert/manufacturer instructions for use labeling associated with the 510(k) clearance issued on April 25, 2025 and to advise those customers that the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test EUA-labeled product inventory may also be used in combination with the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit, which FDA has cleared under 510(k). We also request that Roche Molecular Systems, Inc. instruct customers who have remaining cobas liat SARS-CoV-2, Influenza A/B & RSV control kit EUA product inventory to use their EUA product in combination with the package insert/manufacturer instructions for use labeling associated with the 510(k) clearance on April 25, 2025 and to advise those customers that the cobas liat SARS-CoV-2, Influenza A/B & RSV control kit EUA-labeled product inventory may also be used in combination with the cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, which FDA has cleared under 510(k).

FDA encourages Roche Molecular Systems, Inc. to use all appropriate means (e.g., mail, email, or website link) to notify affected customers of this EUA revocation and provide access to the package insert/manufacturer instructions for use labeling associated with the 510(k) clearance on April 25, 2025.

Notice of this revocation will be published in the *Federal Register*, pursuant to section 564(h)(1) of the Act.

Sincerely,

_____

Ellen J. Flannery, J.D.
Deputy Center Director for Policy
Director, Office of Policy
Center for Devices and Radiological Health
Food and Drug Administration